The anti-EGFR monoclonal antibody Cetuximab was found in a phase II randomized trial to median survival (mOS) of patients with metastatic gastric cancer (6); the application of the anti-HER-2 monoclonal antibody Trastuzumab can make HER-2 patients with positive advanced gastric cancer benefit and have been approved for the first-line treatment of advanced gastric cancer (7); Ramucirumab targeting VEGFR2 has a good anti-tumor effect (8); multi-target tyrosine kinase inhibitor Regorafenib as a multi-target phosphokinase inhibitors have multiple anti-tumor effects (9). Here, EGFR is linked to gastric cancer.